|
[posting]60468560[/posting]In conclusion, while the probability of a US approval versus a CRL are equally weighted at this point of the Priority Review, our teams are striving to satisfy the frequent queries lodged by the FDA. As our Chair recently stated, given the legacy of the Company, we are determined to overcome all conceivable obstacles, and maintain a relentlessness in our approach. |
|
| aus der Diskussion: | CLINUVEL PHARMACEUTICALS LTD |
| Autor (Datum des Eintrages): | Aongrodt (02.05.19 09:33:15) |
| Beitrag: | 10,378 von 22,262 (ID:60468977) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |